CADL•benzinga•
Candel Therapeutics Announces 2025 Milestones, CAN-2409 Updates For PDAC, NSCLC In Q1 2025, BLA Submission For Prostate Cancer In Q4 2026; Phase 3 Data To Be Presented; CAN-3110 Trial Results For rHGG By Q4 2025; $103M Cash To Fund Operations Into Q1 2027
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga